Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122796 | 0.90 | ALDH1A1 (0.41) | JAK3ALDH1A1MEN1KMT2AMERTK | |
| SCHEMBL27224976 | 0.86 | MAPK8 (0.43) | JAK1JAK3MAPK8MAPK9MEN1 | |
| SCHEMBL30990814 | 0.83 | MEN1 (0.42) | JAK1ALDH1A1MEN1KMT2ASYK | |
| SCHEMBL31340873 | 0.83 | SYK (0.40) | JAK3ALDH1A1MEN1KMT2AMERTK | |
| SCHEMBL30873297 | 0.82 | JAK1 (0.59) | JAK1JAK3MAPK8MAPK9ALDH1A1 | |
| SCHEMBL14657356 | 0.82 | JAK1 (0.59) | JAK1JAK3MAPK8MAPK9ALDH1A1 | |
| SCHEMBL31340993 | 0.81 | SYK (0.41) | JAK1JAK3ALDH1A1MEN1KMT2A | |
| SCHEMBL28446204 | 0.79 | JAK1 (0.55) | JAK1JAK3MAPK8MAPK9ALDH1A1 | |
| SCHEMBL28447592 | 0.78 | JAK1 (0.54) | JAK1JAK3MAPK8MAPK9ALDH1A1 | |
| SCHEMBL28446202 | 0.77 | JAK1 (0.53) | JAK1JAK3MAPK8MAPK9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | JAK1 1672/4885JAK3 1555/4885MAPK8 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.